Engineering T7 bacteriophage as a potential DNA vaccine targeting delivery vector

Xu, Hai; Bao, Xi; Wang, Yiwei; Xu, Yue; Deng, Bihua; Lu, Yu; Hou, Jingbo

doi:10.1186/s12985-018-0955-1

Cited by 24 publications

(19 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…is observation provides valuable information on the pharmacokinetic aspects of bacteriophage treatment, which is vital in the context of using bacteriophages as an alternative antimicrobial therapy [47]. It also emphasizes the possibility of using bacteriophages as vectors in drug and gene delivery systems, including therapies targeted towards the brain tissue, gastrointestinal tract, and lung via systemic or local delivery [48][49][50][51]. Furthermore, it also provides a reasonable explanation of the mechanism of direct horizontal gene transfer (HGT) between phages and eukaryotes, discussed in a later section.…”

Section: Bacteriophages Can Penetrate and Disperse Within Amentioning

confidence: 99%

Interactions between Bacteriophages and Eukaryotic Cells

Putra

Lyrawati

2020

Scientifica

View full text Add to dashboard Cite

As the name implies, bacteriophage is a bacterium-specific virus. It infects and kills the bacterial host. Bacteriophages have gained attention as alternative antimicrobial entities in the science community in the western world since the alarming rise of antibiotic resistance among microbes. Although generally considered as prokaryote-specific viruses, recent studies indicate that bacteriophages can interact with eukaryotic organisms, including humans. In the current review, these interactions are divided into two categories, i.e., indirect and direct interactions, with the involvement of bacteriophages, bacteria, and eukaryotes. We discuss bacteriophage-related diseases, transcytosis of bacteriophages, bacteriophage interactions with cancer cells, collaboration of bacteriophages and eukaryotes against bacterial infections, and horizontal gene transfer between bacteriophages and eukaryotes. Such interactions are crucial for understanding and developing bacteriophages as the therapeutic agents and pharmaceutical delivery systems. With the advancement and combination of in silico, in vitro, and in vivo approaches and clinical trials, bacteriophages definitely serve as useful repertoire for biologic target-based drug development to manage many complex diseases in the future.

show abstract

Section: Bacteriophages Can Penetrate and Disperse Within Amentioning

confidence: 99%

Interactions between Bacteriophages and Eukaryotic Cells

Putra

Lyrawati

2020

Scientifica

View full text Add to dashboard Cite

show abstract

“…Use of engineered phages to broaden the host range [137], conversion from lysogenic phages to lytic forms [138,139], expressing cell-penetrating peptides [95] and incorporate enzybiotics such as endolysins [140] and phage encoded cell wall degrading enzymes into their genomes have been shown to be effective in vitro, which have paved a way for future opportunities . For instance, Xu et al reported enhanced internalization of T7 phage by mammalian cells when human immunodeficiency virus type 1 TAT peptide was present on its surface [141]. The authors reported 2-log orders higher uptake of modified phage in mammalian cells (kidney epithelial cells) compared to T7 not modified with TAT peptide [141].…”

Section: Cinquerrui Et Al Proposed a Microfluidics-based Nano-encapsulation Of Phages Inmentioning

confidence: 99%

“…For instance, Xu et al reported enhanced internalization of T7 phage by mammalian cells when human immunodeficiency virus type 1 TAT peptide was present on its surface [141]. The authors reported 2-log orders higher uptake of modified phage in mammalian cells (kidney epithelial cells) compared to T7 not modified with TAT peptide [141]. In another instance, increased internalization of engineered M13 was reported by HeLa cells [142].…”

Section: Cinquerrui Et Al Proposed a Microfluidics-based Nano-encapsulation Of Phages Inmentioning

confidence: 99%

Combatting intracellular pathogens using bacteriophage delivery

Goswami

Sharma

Agarwal

2021

Critical Reviews in Microbiology

View full text Add to dashboard Cite

Intracellular pathogens reside in specialized compartments within the host cells restricting the access of antibiotics. Insufficient intracellular delivery of antibiotics along with several other resistance mechanisms weaken the efficacy of current therapies. An alternative to antibiotic therapy could be bacteriophage (phage) therapy. Although phage therapy has been in practice for a century against various bacterial infections, the efficacy of phages against intracellular bacteria is still being explored. In this review, we will discuss the advancement and challenges in phage therapy, particularly against intracellular bacterial pathogens. Finally, we will highlight the uptake mechanisms and approaches to overcome the challenges to phage therapy against intracellular bacteria.

show abstract

“…Modifying the genes of T7 phage can inactivate the bacteria‐resistant genes. [ 20 , 21 , 22 ] So far, there has not been a review dedicated to the theranostic applications of T7 phage.…”

Section: Introductionmentioning

confidence: 99%

T7 Phage as an Emerging Nanobiomaterial with Genetically Tunable Target Specificity

Hui

Yang

et al. 2021

Advanced Science

View full text Add to dashboard Cite

Bacteriophages, also known as phages, are specific antagonists against bacteria. T7 phage has drawn massive attention in precision medicine owing to its distinctive advantages, such as short replication cycle, ease in displaying peptides and proteins, high stability and cloning efficiency, facile manipulation, and convenient storage. By introducing foreign gene into phage DNA, T7 phage can present foreign peptides or proteins site-specifically on its capsid, enabling it to become a nanoparticle that can be genetically engineered to screen and display a peptide or protein capable of recognizing a specific target with high affinity. This review critically introduces the biomedical use of T7 phage, ranging from the detection of serological biomarkers and bacterial pathogens, recognition of cells or tissues with high affinity, design of gene vectors or vaccines, to targeted therapy of different challenging diseases (e.g., bacterial infection, cancer, neurodegenerative disease, inflammatory disease, and foot-mouth disease). It also discusses perspectives and challenges in exploring T7 phage, including the understanding of its interactions with human body, assembly into scaffolds for tissue regeneration, integration with genome editing, and theranostic use in clinics. As a genetically modifiable biological nanoparticle, T7 phage holds promise as biomedical imaging probes, therapeutic agents, drug and gene carriers, and detection tools.

show abstract

Engineering T7 bacteriophage as a potential DNA vaccine targeting delivery vector

Cited by 24 publications

References 37 publications

Interactions between Bacteriophages and Eukaryotic Cells

Interactions between Bacteriophages and Eukaryotic Cells

Combatting intracellular pathogens using bacteriophage delivery

T7 Phage as an Emerging Nanobiomaterial with Genetically Tunable Target Specificity

Contact Info

Product

Resources

About